Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[INTRODUCTION] Managing urothelial carcinoma with immune checkpoint inhibitors requires addressing issues beyond clinical outcomes.
APA
Al Armashi AR, Gong J, et al. (2026). Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.. Expert review of anticancer therapy, 1-15. https://doi.org/10.1080/14737140.2026.2628071
MLA
Al Armashi AR, et al.. "Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.." Expert review of anticancer therapy, 2026, pp. 1-15.
PMID
41660943 ↗
Abstract 한글 요약
[INTRODUCTION] Managing urothelial carcinoma with immune checkpoint inhibitors requires addressing issues beyond clinical outcomes. Implementation difficulties affect most patients, predictive biomarkers show limited utility, and treatment discontinuation from toxicity remains problematic.
[AREAS COVERED] This article integrates clinical trials, systematic reviews, health-system evaluations, and guidelines from 2016 to 2025. We detail limitations of programmed death-ligand 1 (PD-L1) expression, panel-based tumor mutational burden (TMB), clinic-ready toxicity pathways, immune-appropriate response criteria (iRECIST), pseudoprogression, hyperprogression, post-ICI sequencing (FGFR3 alterations, enfortumab vedotin-based therapy, chemotherapy, trials), and delivery models (navigation, electronic patient-reported outcomes, telemedicine, payment structures).
[EXPERT OPINION] Optimizing systemic frameworks for immunotherapy care requires careful evaluation of functional status, protocols for immune-related adverse events management, standardization for assessments of clinical responses, and ensuring equitable access to care. ctDNA and AI-assisted radiomics are promising adjuncts to clinical care, but still require multi-center prospective validation before adoption into routine practice.
[AREAS COVERED] This article integrates clinical trials, systematic reviews, health-system evaluations, and guidelines from 2016 to 2025. We detail limitations of programmed death-ligand 1 (PD-L1) expression, panel-based tumor mutational burden (TMB), clinic-ready toxicity pathways, immune-appropriate response criteria (iRECIST), pseudoprogression, hyperprogression, post-ICI sequencing (FGFR3 alterations, enfortumab vedotin-based therapy, chemotherapy, trials), and delivery models (navigation, electronic patient-reported outcomes, telemedicine, payment structures).
[EXPERT OPINION] Optimizing systemic frameworks for immunotherapy care requires careful evaluation of functional status, protocols for immune-related adverse events management, standardization for assessments of clinical responses, and ensuring equitable access to care. ctDNA and AI-assisted radiomics are promising adjuncts to clinical care, but still require multi-center prospective validation before adoption into routine practice.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.